A longer acting rFVIII, safe and effective

In this issue of Blood, Mahlangu et al describe a well-designed and executed phase 3 multicenter study of a recombinant factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hemophilia A.

Saved in:
Bibliographic Details
Published in:Blood 2014-01, Vol.123 (3), p.304-305
Main Author: Lusher, Jeanne M.
Format: Article
Language:English
Subjects:
Factor VIII - therapeutic use
Hemophilia A - drug therapy
Humans
Immunoglobulin Fc Fragments - therapeutic use
Male
Recombinant Fusion Proteins - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this issue of Blood, Mahlangu et al describe a well-designed and executed phase 3 multicenter study of a recombinant factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hemophilia A.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2013-12-539825